Lokpal S. Bhatia

Tremona Road
Southampton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.

Journal: European journal of clinical nutrition

Published: August 16, 2017

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.

Journal: European journal of clinical nutrition

Published: September 15, 2016

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.

Journal: Diabetologia

Published: January 19, 2016

Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.

Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.

Journal: Atherosclerosis

Published: July 14, 2015

Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.

Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.

Journal: Journal of hepatology

Published: April 12, 2015

Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.

Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.

Journal: Diabetologia

Published: March 12, 2015

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.

Journal: Hepatology (Baltimore, Md.)

Published: April 25, 2014

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].

Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].

Journal: Contemporary clinical trials

Published: October 24, 2013

Nonalcoholic fatty liver disease and vascular risk.

Nonalcoholic fatty liver disease and vascular risk.

Journal: Current opinion in cardiology

Published: May 19, 2012

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

Journal: European heart journal

Published: March 13, 2012

Clinical implications of ST-segment non-resolution after thrombolysis for myocardial infarction.

Clinical implications of ST-segment non-resolution after thrombolysis for myocardial infarction.

Journal: Journal of the Royal Society of Medicine

Published: December 03, 2004

Showing 1-11 of 11

Last Updated: 09/26/2026